Sharemaestro Newsreel

Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue

Assembly Biosciences (ASMB) boosts cash to $320M and narrows loss

Moleculin Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Polaryx Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Cibus (CBUS) narrows Q2 2026 loss as cash burn falls and regulatory tailwinds build

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Celcuity GAAP EPS of -$1.44 misses by $0.28

* Celcuity press release [https://seekingalpha.com/pr/20619145-celcuity-inc-reports-release-of-second-quarter-2026-financial-results-and-provides-corporate] (CELC [https://seekingalpha.com/symbol/CELC]): Q2 GAAP EPS of -$1.44 misses by $0.28. * Total operating expenses were $66.1 million for the second quarter of 2026, compared to $44.0 million for the prior year period. Research and development (“R&D”) expenses were $31.1 …

Assembly Biosciences: Q2 Earnings Snapshot

Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW

This article focuses on the "Price to book forward" financial metric for Humacyte, Inc., traded on NASDAQ under the symbol HUMAW. It provides a snapshot of this financial data point within the context of the company's financial overview on a trading platform. The content …

ALPHA COGNITION ($ACOG) Releases Q2 2026 Earnings, Stock Rises

ALPHA COGNITION ($ACOG) announced its Q2 2026 earnings, reporting -$0.40 per share, which met analyst estimates, and revenue of $6,090,000, exceeding expectations. Following the announcement, the stock price rose by 8.7%. The article also details recent insider trading activity, with significant purchases, and outlines …

MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics has reported its financial results for Q2 2026, highlighting positive outcomes from its Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia, which is now advancing to Phase 3. The company is primarily focusing its resources on ML-007C-MA, with ongoing enrollment for the …

Vivani Medical (VANI) widens GLP‑1 pipeline, funds runway into Q2 2027

Vivani Medical (VANI) has reported a net loss of $6.4 million for Q2 2026 and $13.2 million for the first half of 2026, with cash and equivalents totaling $19.9 million, which is projected to fund operations into Q2 2027. The company is advancing its …

Form 8K Vivani Medical Inc For: 13 August By Investing.com

This article reports on the filing of a Form 8K by Vivani Medical Inc. on August 13th, as tracked by Investing.com. The brief mention indicates a financial disclosure event for the company, with the stock symbol VANI noted to have experienced a -2.19% change.

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

Vivani Medical reported its second-quarter 2026 financial results, highlighting significant progress in its clinical development, including the successful dosing of all participants in its SLIM-1 Phase 1 trial for NPM-139, a semaglutide implant for chronic weight management. The company also announced a non-exclusive agreement …

20 Participants Dosed in Semaglutide Trial; Data Due in November

Vivani Medical (VANI) reported its Q2 2026 financial results, highlighting the successful dosing of all 20 participants in its Phase 1 SLIM-1™ trial for NPM-139, a semaglutide implant, with top-line data expected in November 2026. The company also announced a non-exclusive agreement with Novo …

Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G

A group of Deerfield entities and James E. Flynn have filed an amended Schedule 13G, revealing a collective beneficial ownership of 5,006,104 shares of Cogent Biosciences (COGT) common stock, which represents 2.88% of the outstanding class. The filing indicates shared voting and dispositive power …

Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Eikon Therapeutics reported its second-quarter 2026 financial results, highlighting significant clinical advancements across its oncology portfolio, particularly with abstracts accepted for the ESMO Congress 2026. The company detailed progress in clinical trials for its drug candidates EIK1001, EIK1003, EIK1004, and EIK1005, and announced key …

Kyntra Bio (Nasdaq: KYNB) turns Q2 profit as deconsolidation gain offsets cash burn

Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash

Yarrow Bioscience (VYNE) halves losses and completes transformative merger with Yarrow

Yarrow Bioscience (formerly VYNE Therapeutics) reported a significant reduction in its net loss for the six months ended June 30, 2026, dropping to $6.6 million from $14.4 million a year prior, largely due to decreased R&D spending as legacy programs were wound down. The …

Earnings Flash (ALMS) Alumis Inc. Reports Q2 Revenue $1.7M, Vs. FactSet Est of $3.5M

Alumis Inc. (ALMS) reported its second-quarter revenue, which came in at $1.7 million. This figure was significantly lower than FactSet's estimated revenue of $3.5 million, indicating a miss on analyst expectations for the quarter.

Dianthus Therapeutics (DNTH): Wellington group discloses 3.23M-share, 5.9% passive stake

Wellington Management entities have disclosed a passive beneficial ownership stake of approximately 5.9% (3,229,882 shares) in Dianthus Therapeutics (DNTH) through a Schedule 13G filing. The shares are held by clients of various Wellington investment advisers, with Wellington reporting shared voting and dispositive power but …

Assembly Biosciences Projects Operations Funded Into 2029 With $75M Gilead Payment Due

Assembly Biosciences reported its Q2 2026 financial results, revealing a projected cash runway into 2029, bolstered by a recent $115 million financing and an anticipated $75 million payment from Gilead. The company is advancing its ABI-6250 program into Phase 2 studies for cholestatic liver …

Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026

Kodiak Sciences reported a Q2 2026 net loss of $65.6 million and ended the quarter with $125.9 million in cash, expected to fund operations into 2027. The company reiterated upcoming Phase 3 topline readouts for DAYBREAK in September 2026 and PEAK Pivotal Analysis 1 …

Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients

Wellington Management Group LLP and its affiliates have reported a passive ownership stake of approximately 1.47% in Xenon Pharmaceuticals Inc. (XENE) common stock. This stake, representing 1,425,492 shares, is held for advisory clients across various Wellington investment entities, with no single client owning more …

Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64

Xenon Pharmaceuticals director Steven Gannon sold 10,000 Common Shares on August 11, 2026, at a weighted-average price of $64.055 per share. The shares were sold in multiple transactions ranging from $64.0517 to $64.078. Following this transaction, Gannon directly holds 1,870 Common Shares of Xenon …

Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12

Celcuity Inc. (CELC) reported a Q2 adjusted loss of $1.07 per share, which was better than the FactSet estimate of $-1.12 per share. The article, published on August 13, 2026, also noted that Celcuity's Q2 adjusted loss widened. This news follows several recent developments …

Daré Bioscience launches Flora Sync, its first directly commercialized product

Daré Bioscience (NASDAQ: DARE) reported Q2 2026 revenue of $0.19 million, a net loss of $3.0 million, and $12.6 million in cash and equivalents. The company announced the launch of Flora Sync LF5, its first directly commercialized product, which began generating revenue in July …

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Daré Bioscience reported its Q2 2026 financial results, highlighting significant progress in its multi-product women's health strategy. The company launched Flora Sync LF5 and is preparing for national dispensing of DARE to PLAY Sildenafil Cream, expecting initial revenue in Q3 2026. Daré also provided …

Dare Bioscience, Inc. 2026: Revenue $187.55K, EPS ($0.2) — 10-Q Summary

Dare Bioscience, Inc. reported its 2026 quarterly results, with revenue of $187.55K and a net loss of ($2.98M), which is an improvement from the prior year's loss. The company saw revenue growth due to Gates Foundation agreements and the launch of new products and …

MacroGenics GAAP EPS of -$1.10 misses by $1.02, revenue of $32.83M misses by $26.31M

* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $1.02. * Revenue of $32.83M (+377.9% Y/Y) misses by $26.31M. MORE ON MACROGENICS * MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important [https://seekingalpha.com/article/4925873-macrogenics-whipsaws-on-clinical-data-but-the-big-picture-is-still-important] * MacroGenics: 'Hold' …

4D Molecular Therapeutics (FDMT) posts $141.7M first-half 2026 net loss

Mark Mossler (CCCC) files to sell 15,000 shares after recent stock sales

Mark Mossler has filed a Form 144 to sell 15,000 shares of C4 Therapeutics, Inc. (CCCC) common stock, acquired through a stock option exercise. The aggregate market value of this planned sale is $61,072.50, and the transaction is expected to occur on or after …

Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028

CAMP4 Therapeutics reported a wider net loss of $33.5 million in Q2 2026, primarily due to a non-cash loss from a derivative liability. Despite this, the company's research and collaboration revenue increased, and it successfully extended its cash runway through the end of 2028 …

CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges

CAMP4 Therapeutics reported a widened net loss of $51.86 million for the six months ended June 30, 2026, primarily due to a $27.12 million non-cash charge from the remeasurement of a derivative tranche liability. Despite the loss, the company extended its cash runway through …